Evidence map›Paper›PMID 30806082›Full record

ReviewCNS oncology2019

Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice.

Ugonma N Chukwueke, Patrick Y Wen

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in CNS oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06258018 (A Phase I-II Study of Niraparib Plus Temozolomide "One Week on, One Week Off" in Patients With Recurrent Isocitrate Dehydrogenase), which is not on this map. Cited by 157 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
157citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06258018 phase1 / phase2not yet recruitingnot on this mapstarted 2024, after this paper: background citation

A Phase I-II Study of Niraparib Plus Temozolomide "One Week on, One Week Off" in Patients With Recurrent Isocitrate Dehydrogenase (IDH) Wild Type Glioblastoma and IDH Mutant Gliomas.

TypeinterventionalSponsorArmando Santoro, MDRan2024 to 2027Enrolled86ConditionsGlioma, MalignantArmsTemodal, Niraparib
3 · Its place in the literature

Who cites it

157 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Current issues in molecular biology · 2026
    Article
  19. Significant clinical and radiologic response to targeted therapy in pediatric cervicomedullary low-grade gliomas harboring the BRAFV600E mutation.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025
    Article
  20. Article

97 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ugonma N ChukwuekeDepartment of Medical Oncology, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Patrick Y WenDepartment of Medical Oncology, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Clinical Trials as TopicPractice Patterns, Physicians'Central Nervous System NeoplasmsHumansTreatment Outcomebevacizumabclinical trialsCNS tumorsimmune checkpoint inhibitorspediatric brain tumor imagingpseudoprogresionpseudoresponseRANOresponse criteria

Identifiers

PMID30806082
PMCPMC6499019

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.